Prasert Thongcharoen

Summary

Affiliation: Mahidol University
Country: Thailand

Publications

  1. ncbi Cross-clade immunogenicity and antigen-sparing with an AS03(A)-adjuvanted prepandemic influenza vaccine in a Thai population
    Prasert Thongcharoen
    Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
    J Med Assoc Thai 94:916-26. 2011
  2. ncbi A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost
    Prasert Thongcharoen
    Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand
    J Acquir Immune Defic Syndr 46:48-55. 2007
  3. ncbi Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand
    Chitraporn Karnasuta
    Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
    Vaccine 23:2522-9. 2005
  4. ncbi Enhanced sensitivity of detection of cytotoxic T lymphocyte responses to HIV type 1 proteins using an extended in vitro stimulation period for measuring effector function in volunteers enrolled in an ALVAC-HIV phase I/II prime boost vaccine trial in Thail
    Wannee Kantakamalakul
    Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
    AIDS Res Hum Retroviruses 20:642-4. 2004
  5. ncbi HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E
    Robert Paris
    Department of Retrovirology and Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
    Vaccine 30:832-6. 2012
  6. ncbi Serological response to the 2009 pandemic influenza A (H1N1) virus for disease diagnosis and estimating the infection rate in Thai population
    Hatairat Lerdsamran
    Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
    PLoS ONE 6:e16164. 2011
  7. ncbi Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults
    Punnee Pitisuttithum
    Vaccine Trial Centre, Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Siriraj Hospital, Mahidol University, 420 6 Rajvithi Road, Bangkok 10400, Thailand
    J Infect Dis 188:219-27. 2003
  8. ncbi Antibody responses after dose-sparing intradermal influenza vaccination
    Prasert Auewarakul
    Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
    Vaccine 25:659-63. 2007
  9. ncbi Vaccines for a potential influenza pandemic
    Prasert Auewarakul
    Mahidol University, Department of Microbiology, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand
    Future Microbiol 2:345-9. 2007
  10. ncbi Prevalence of rabies virus and Hantaan virus infections in commensal rodents and shrews trapped in Bangkok
    Wannee Kantakamalakul
    Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
    J Med Assoc Thai 86:1008-14. 2003

Collaborators

Detail Information

Publications13

  1. ncbi Cross-clade immunogenicity and antigen-sparing with an AS03(A)-adjuvanted prepandemic influenza vaccine in a Thai population
    Prasert Thongcharoen
    Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
    J Med Assoc Thai 94:916-26. 2011
    ..The immunogenicity and safety of the vaccine in the Thai population are reported herein...
  2. ncbi A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost
    Prasert Thongcharoen
    Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand
    J Acquir Immune Defic Syndr 46:48-55. 2007
    ..A prime-boost HIV-1 vaccine trial assessing safety and immunogenicity was conducted in Thailand as part of an evaluation of candidate regimens for a phase 3 efficacy trial...
  3. ncbi Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand
    Chitraporn Karnasuta
    Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
    Vaccine 23:2522-9. 2005
    ..The results demonstrate that this HIV vaccine is a potent inducer of ADCC activity and may be an additional protection of this prime-boost vaccine in preventing HIV disease...
  4. ncbi Enhanced sensitivity of detection of cytotoxic T lymphocyte responses to HIV type 1 proteins using an extended in vitro stimulation period for measuring effector function in volunteers enrolled in an ALVAC-HIV phase I/II prime boost vaccine trial in Thail
    Wannee Kantakamalakul
    Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
    AIDS Res Hum Retroviruses 20:642-4. 2004
    ..These results imply that extension of the IVS period may increase the sensitivity of the CRA when measuring HIV-specific CTL in ALVAC-HIV prime-boost recipients without compromising specificity...
  5. ncbi HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E
    Robert Paris
    Department of Retrovirology and Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
    Vaccine 30:832-6. 2012
    ..009). These data suggest that the lack of response to a vaccine designed to induce clade-specific NAb to HIV-1 is associated with the presence of certain HLA class II alleles and heterodimers in some Southeast Asians...
  6. ncbi Serological response to the 2009 pandemic influenza A (H1N1) virus for disease diagnosis and estimating the infection rate in Thai population
    Hatairat Lerdsamran
    Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
    PLoS ONE 6:e16164. 2011
    ..Individuals infected with the 2009 pandemic virus A(H1N1) developed serological response which can be measured by hemagglutination-inhibition (HI) and microneutralization (microNT) assays...
  7. ncbi Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults
    Punnee Pitisuttithum
    Vaccine Trial Centre, Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Siriraj Hospital, Mahidol University, 420 6 Rajvithi Road, Bangkok 10400, Thailand
    J Infect Dis 188:219-27. 2003
    ..There was no evidence of antigenic interference in HIV-specific humoral or cellular responses. The gp120 Thai E and SF2 vaccines were safe and immunogenic in combination and could be advanced into phase 3 testing...
  8. ncbi Antibody responses after dose-sparing intradermal influenza vaccination
    Prasert Auewarakul
    Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
    Vaccine 25:659-63. 2007
    ....
  9. ncbi Vaccines for a potential influenza pandemic
    Prasert Auewarakul
    Mahidol University, Department of Microbiology, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand
    Future Microbiol 2:345-9. 2007
    ..Here we discuss obstacles and progress in the development of candidate vaccines for H5N1 avian influenza, currently the most threatening virus...
  10. ncbi Prevalence of rabies virus and Hantaan virus infections in commensal rodents and shrews trapped in Bangkok
    Wannee Kantakamalakul
    Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
    J Med Assoc Thai 86:1008-14. 2003
    ....
  11. ncbi HIV/AIDS preventive vaccine 'prime-boost' phase III trial: foundations and initial lessons learned from Thailand
    Supachai Rerks-Ngarm
    AIDS 20:1471-9. 2006
  12. ncbi The oral AIDS vaccine,V-1 Immunitor
    Prasert Thongcharoen
    HIV Clin Trials 5:257-8. 2004
  13. ncbi V-1 immunitor
    Prasert Thongcharoen
    Viral Immunol 17:457. 2004